Massachusetts General Hospital

Boston, MA

Sorting 7 by

Accepting patients

REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
  • MYB mRNA Degrader
  • Phase 1

Accepting patients

PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
  • IDH1 Inhibitor
  • Randomization
  • Phase 3

Accepting patients

TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
  • T Cell (Allogeneic)
  • Phase 1
  • Has results

Accepting patients

BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  • GSPT1 Degrader
  • CD33
  • Phase 1

Accepting patients

Safety Study of Cord Blood Units

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Phase 2

Not currently accepting

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial

Accepting patients

SEA-CD70

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
  • Monoclonal Antibody
  • CD70
  • Phase 1